Pharsight

Oxycontin patents expiration

OXYCONTIN's oppositions filed in EPO

OXYCONTIN Litigations

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(9 months from now)

US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(9 months from now)

US10407434 PURDUE PHARMA LP Process for preparing oxycodone compositions
Mar, 2025

(9 months from now)

US10696684 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5508042 PURDUE PHARMA LP Controlled release oxycodone compositions
Apr, 2013

(11 years ago)

US6488963 PURDUE PHARMA LP Hot-melt extrudable pharmaceutical formulation
Jun, 2017

(6 years ago)

US8337888 PURDUE PHARMA LP Pharmaceutical formulation containing gelling agent
Aug, 2022

(1 year, 10 months ago)

US9060976 PURDUE PHARMA LP Pharmaceutical formulation containing gelling agent
Aug, 2022

(1 year, 10 months ago)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(a year ago)

US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(a year ago)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(6 months ago)

US10675278 PURDUE PHARMA LP Crush resistant delayed-release dosage forms
Nov, 2023

(6 months ago)

US8114383 PURDUE PHARMA LP Abuse-proofed dosage form
Oct, 2024

(3 months from now)

US7683072 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(9 months from now)

US7674799 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(9 months from now)

US7674800 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(9 months from now)

US7776314 PURDUE PHARMA LP Abuse-proofed dosage system
Apr, 2025

(10 months from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US8808741 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492392 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9775808 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US8894988 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492393 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

US8894987 PURDUE PHARMA LP Tamper resistant dosage forms
Mar, 2030

(5 years from now)

Oxycontin is owned by Purdue Pharma Lp.

Oxycontin contains Oxycodone Hydrochloride.

Oxycontin has a total of 30 drug patents out of which 9 drug patents have expired.

Expired drug patents of Oxycontin are:

  • US5508042
  • US6488963
  • US8337888
  • US9060976
  • US10369109
  • US9675610
  • US10130591
  • US8309060
  • US10675278

Oxycontin was authorised for market use on 12 December, 1995.

Oxycontin is available in tablet, extended release;oral dosage forms.

Oxycontin can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate, management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The generics of Oxycontin are possible to be released after 29 March, 2030.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date:

12 December, 1995

Treatment:

Management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time; Management of pain severe enough to require daily, around-the-clock, long ...

Dosage:

TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

OXYCONTIN family patents

Family Patents